医学
2型糖尿病
内科学
糖尿病
疾病
认知
内分泌学
精神科
作者
Bastiaan E. de Galan,Sophia Zoungas,John Chalmers,Craig S. Anderson,Carole Dufouil,Avinesh Pillai,Mark E. Cooper,Diederick E. Grobbee,Maree L. Hackett,Pavel Hamet,Simon Heller,Lisheng Liu,Stephen MacMahon,Giuseppe Mancia,Bruce Neal,Chang Yu Pan,Anushka Patel,Neil Poulter,F. Travert,Mark Woodward
出处
期刊:Diabetologia
[Springer Nature]
日期:2009-08-18
卷期号:52 (11): 2328-2336
被引量:200
标识
DOI:10.1007/s00125-009-1484-7
摘要
The relationship between cognitive function, cardiovascular disease and premature death is not well established in patients with type 2 diabetes. We assessed the effects of cognitive function in 11,140 patients with type 2 diabetes who participated in the Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified Release Controlled Evaluation (ADVANCE) trial. Furthermore, we tested whether level of cognitive function altered the beneficial effects of the BP-lowering and glycaemic-control regimens in the trial.Cognitive function was assessed using the Mini Mental State Examination at baseline, and defined by scores 28-30 ('normal', n = 8,689), 24-27 ('mild dysfunction', n = 2,231) and <24 ('severe dysfunction', n = 212). Risks of major cardiovascular events, death and hypoglycaemia and interactions with treatment were assessed using Cox proportional hazards analysis.Relative to normal function, both mild and severe cognitive dysfunction significantly increased the multiple-adjusted risks of major cardiovascular events (HR 1.27, 95% CI 1.11-1.46 and 1.42, 95% CI 1.01-1.99; both p < 0.05), cardiovascular death (1.41, 95% CI 1.16-1.71 and 1.56, 95% CI 0.99-2.46; both p
科研通智能强力驱动
Strongly Powered by AbleSci AI